Thermo Fisher Scientific Product — Consolidated revenues increased by 5.5% to $6.49B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 5.5%, from $6.15B to $6.49B. This is a positive signal — higher values indicate stronger performance for this metric.
An increase indicates strong market demand and successful product adoption, while a decrease may signal market saturation or competitive pressure on hardware and consumable sales.
This metric represents the total gross income generated from the sale of physical goods, including scientific instrument...
Peers in the life sciences and diagnostics sector typically report product revenue separately from service revenue to distinguish between recurring consumable sales and project-based service contracts.
tmo_segment_product_revenues_consolidated_revenues| Q2 '21 | Q1 '22 | Q2 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q3 '24 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|
| Value | $7.21B | $8.02B | $7.00B | $6.31B | $6.31B | $6.31B | $6.31B | $6.15B | $6.49B |
| QoQ Change | — | +11.1% | -12.6% | -9.9% | +0.0% | +0.0% | +0.0% | -2.6% | +5.5% |
| YoY Change | — | — | -2.9% | -21.3% | -9.9% | — | — | -2.6% | +5.5% |
We use cookies for analytics. See our Privacy and Cookie Policy.